Sartorius opens $23M bioreactor plant

Sartorius CEO Dr. Joachim Kreuzburg--image courtesy of Sartorius

Biopharma supplier Sartorius is expanding again. Only three months after completing an addition to a plant in Puerto Rico, the company has opened a new production facility in Germany to make bioreactors.

The German company invested €18 million ($23.3 million) to build the 10,000-square-foot production facility and offices in Guxhagen for about 240 employees. The new complex replaces an older plant in Melsungen that could no longer produce the capacity for growing demand.  

"The new plant enables us to substantially enhance our manufacturing processes and creates additional capacity for us in view of the rising demand for biopharmaceutical production equipment," Sartorius CEO Joachim Kreuzburg said in a statement. "As a result, we are optimally prepared for further expansion, especially for single-use bioreactors."

In June, Sartorius finished up a €16 million ($20 million) expansion to a plant in Yauco, Puerto Rico, for producing filters and single-use bags. The nearly 54,000-square-foot, "eco-friendly" building has two clean rooms for filter and bag manufacture, labs and offices. Sartorius is relocating bag manufacturing in Concord, CA, to the Puerto Rico facility by the end of the year. It will add about 120 new employees at the Yauco plant, nearly doubling the workforce.

The company says the expansion in Puerto Rico is to keep up with escalating orders for single-use products. It says filters and bags are increasingly being requested as combined, sterile-packaged and ready-to-connect single-use assemblies.

- here's the release on the Guxhagen plant
- get more on the Puerto Rico plant

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.